ࡱ> zaNsܦ?I8Z( UUUUUUUUUUUUUUUUza 60ߵ!| :( UUUUUUUUUUUUUUUU`!I߼0\t_.`ExeX xN53kMhTCCD*nU4[hN\FiO(*)n-ѠDPHhQ3W_V}֞fzg$Lf|fk%Zb^_Oߺp]dZ`4d`v]״0o߾ <Ģ Yl֗#NOz t]2_!yq-#N&S'JW:F-"5Vɔ^> zO~_Z䷧~<?͸_c?g#+qg>P:TbzI'j䏦~ ЪїS ^5^ jTo_w|+} j8xN E#Z(q"^6ɲH#kX.dX*j18KX\tb38+;*(ӌXHp%`9tx!݂h;c81˒`\Ӵ#8e{D&fdסX-/3f2p3t1ySvs!wch=cFx͊ģVU\lƗ֘bii\O~lFK%41xV1.2Ef+o1-0@k [28j}`C#t#q4ȵg!;✮0g:uCw t0-$@7כֿGZ8dr.S#d'B0;?S.;p8Arq~ @kȄt(C EA4p;^~k5ecL7ͥTf.43Th)AÍα721&q}U=:D+8C*pan>f\.2Gs^6#8#ʠJ6xk-qƐfv?|o޼wo<3-}̽Nu"O7֯W^0Vӌ\x,7̀pp>^3Rl#X]?z[त7GV^^/BW/*F6`=0,#`3d34#1HmUZhbK; kkI1{? -Ŏn@wj7R޽]˘޽ >S[>(VxH':udpz+G~ *3ߡ~g# 9S-"m,sq? ? {3Z0D /xRDluX5CNtI &e0c)[Q-Ek|޻|8_3 ๎y3y,Ϊsgb?0b8ǦT~. 1\56\ALb*/kP# SH1t\d\ 8+Ι-o&ZX M-X3bc79efL2|F;:N}-}8}wO'gN}|=mtg 3^77v3Ycjf:23Q-kϙ5 p70׃Yjig-l{s-r\~2O(lG3Rs873H1CK/]hрٗFWz|*иR4\-uf;}8. L0_h˼'1XK_M>FhkC] 4CGS8}ͨja{9mz,QN渇2*Tjy;4HSz4vϨAͳiH͊xمLl!Yb5Xr8W=]inݦ:$2|vcϕe7*/tZ@=۠ܞ ?ڹ8N/tN'xI=N8ϕN[xh 縤Vl12$.B(<>!`ȅll^$A*D9Gq3sM=@TP$}!tE`ON1EypvGx*c9^6NKۇ-xo"zX![T۵H4Ec8n6 8Ƞ Lv؂" &Ԋh Q;12h0tjA; 5a݀~^G;c^XHe0NU~UDcv0I-.,fRa}tk]G#q>{q87Zwx2r_ ;XNa>0L9p($  V8o}^o;QzU^ʶwCth@G4 p&vl.eJ~h$Wh(͠.:IVSWRu^c)=H#\&,kipCc?dqV,|z|eNu _qGgU9!K`-Fmp]xڮ]{I:gs85󨍗4R iɿSVR|̕31< =! . uڟ:kNljFp?t˟@=#+S#m+L $W|>xZQlTEvK@Ĭ`-b6P+ l**TGm"DCaL%TBLc,!MMH,D>1i^‡μ;]foۥ$'oޜλoffWD)bЯ S&RWTols \cb/- xxW 5>  $WCx˞gkui,F$}"=P"jjnѹ.+?^۷#V!)>6anOO5F*)dzcێu`yD 4 >AR=s!JW -]gߛߗVa>-f7 >)GG|{|X/R)o ͡[w^Іz8@=I>3Fۢ_7׼Lu~;CZ-l]xK(Ub/}%y6 KdG!oʔp~D2}Zclc/re؀l?=\k[!:>}`Kuߜ{b.x[Y3?CL Xyt}/#]ȵÖIZ5f7}eO@,'s O%Fꏒ8(s]KY%^e_x1 sU?ݚp:ws g:לE׈,N:币obQG3:C`Cr7ϣptCR\4I(cqBqOsFj1(D?gI2W+YBq>NH_8x j\iFV<֑V:h֟4ϿO\k8{֝|}k=|Zi7 YI' |##Ba'JKzpNc?&a ~-x+QG1'P{Henc~*ʎuh*z4F[Nvԭ'HN ҭuVD]kۿ( a]˩)tW94-9쏠Y&>fwfAs irLv-gkGwkiY] ַ?[[h/To/֢J/Kv\ ;tk!wD.\d,>]>L/˲~rupɎ5̎dǵ" 횐k§+S=Wކcv?fz]EϘm.{FbCDm/fi4S{Yֳ-^o_m_~Js7_yIZ.[*O4!:0cl<9pRsx$c?<@!O5W}ZtΗzn(U扝7V0g9qWJ7y_SI{@@=H3i6fM@.1Yv>xZ]lU>gv] vf슀Pe% HZ~􁒘bRM5ȃb XCÓ>IH6!ؚ^Μ{]wss̹sMTQi@(7$W@hG0ܿ$D/7T1̡$]6@݊7,BeQ+MQSޣT06in3 ࠗg4擝g=GO -Sfsi|UlRrQcYFT9YP%[ay;!?5_ͱL/H|2;F1~Jtݶ/vo_ cB ~ ~VUKc21ELȭoAۨoL~w ~JS?&xZ!e_P: an-]+|E_++{x?YLEdHUe.;^ey_b1OnF#7+|nqHG5/S*kijK-s9;a;$I7nv;?ur + ,Y[6ڱMZ(áY _[EBɋs2!ky9x_bb?$r0A8E_7I1s? D }?1H@|`61]Ox:`tacr}N|xjeLeLe,4^b*e@e@e 4^^ˠˠ`Tz뱗^ >à Ooc(yP3GF,p}CA~xg=3(0!.&^d|}G;b Ob1='{.xKK५xI/it%atxix2!2!2z?d}`˙\|^T3j!RYOTo!s=DwzcNge?W{m=v|NDߤz7mZj__uvR=S}œDS}6-㯳.'A~1;'Ci'|_0#90ٴ׊:wTтyeȳ85-G7ߟHۨOn7h?h_Un\Nnd_Ӹ۰[k_U^Ă*/ɋ(<6*ZjbNpNgfr*Zjb>p>Y7E[=/W9~vy- ?bz='T9?1m\\دy@+tNd[I/1Yv>xZ]hW>wvcQdiڍU6MtEHK'4ML?`4-iB)B*>X%PD}P|Dܙsg3cV]wΜ;gwϽsglATT8"؛[_Y-x: agX"RMP} ێ[Ov"U#eg:35{<3IHsɯ{_y'*=P:l>]o/s}^ћ}DRHk;BvCqcЎ ſr9 7,"(+Sǿ+O3y373ycL~ٿ䗙|ɇ{J ŰHAqHrtR6꺕`As9^|bQ{E37]&uϋ,}9vA~&؃nַՔwbM5ry(|HzbGOna綖]eO0,;Zv׆ևd-^G~>h)ƈ~/pX-&?" ?枹+B ȟi~%^&J~foD|<)xB7F;_ɇ;/u /u /u%K%,1^Z^Z^Z ԧϟq&ECo c3ǻ0^~6x?+ πwg;3! ȯ;;Bgw_x~ /K(Q%_O Z5>/ʘ^pQ4o|"AHCx"u mkXYgf}.1;OG!Q|eC@e}1_O(e]%1(Fc*Xs51A5485hN# ec+Xs0A$8"N"ec>-~ү u>,Cx:یאzQ68f8sIJ&:w !MH~VOwӫd%K]ݕ {Xk(ߗ}"߫}qAoc~}/,{SAqEd};=d}{Q7A5=P2QFY&ׄbAH]H% /!miFmIv"Msi:^M1m+YemNO!zO#[:Aad[\^)Ywtkw*R_=#UW}ӣYľwwhR{m{m>)Mu"!Fg#[9g/w֝rSl#g1ߵl:݇>cxѫr 6&`\uq >fT __Y5幆LiT[gpTx8ް ?^ƨD_piڋ9wмpp*"bQ`0cu6>+J6#Zڅ ^z\?Eân ~2!MuQ8¾?JG ާ!P_yռT@=Dmc)|01Yv>xZ]lTE>.)4MVʿJbO`aC*Q4ŖWŸy0'%> >$  /ăg={v޽t1ݜ=sϜo̝*rW&V >sAj6+T:6k:FDTIv *tf3 `MƳDs{O -Sdum%(ͤ rkL(:iPN ň/Zև!>%/}؉%/}؁-{F[;#{FL-`;#/w ڜW_|x2M}7bƋ+ %Ƌ+ %Ƌ+ %Ƌ+ %Ƌ+ ?aWw8yhs]|z2ͽ{@!bW|>:JwJ4Jwye5aߏM;ޕl^qXyԨ j!a[ ye=YԞg)oS{ğrOX>9D]T|#呋r^[I_?i/}Tt&}>@QrO\.3IGs>Y!Zc2Unx4dHn7U~΍k3Sn8.-ɼyqyq}mxu2'rN܂~Nc_;-D.|p%}ěN^&Rz8l:VbegZL>jKd6msω vkʕՊ4O~} J΋=[i\nbR~uBayenoG^c]B%"l[l ̙B͋#l|/AK,6dA'yIYwaR=,S=Eؼ4U,UEؼeۇʓy\ƹ/\y]7a+ v#izf9,n+݃|"|ݚ7nwHvhձĀw}-4x}K"5:>'_oi,_ӱ- WjTs8{o|u.B٧E|SuR˓uTq剤?UNdߕC!wxz_}ʾݣ;{tWքj>{btT z9*vh^Uy'CW[#x2"xla˗<8WqXt^ɹvGWD/3&pM ' Ayί񪞿5n ^W hm |jX:}f7 ^??^*n a2ްomF=!NS=̿!(   m+? Chart MSGraph.Chart.804Microsoft Graph 2000 Chart0w<@ Chart MSGraph.Chart.804Microsoft Graph 2000 Chart0u>A Chart MSGraph.Chart.804Microsoft Graph 2000 Chart0yCB Chart MSGraph.Chart.804Microsoft Graph 2000 Chartb/ 0DTimes New Roman30Wo 0DTahomaew Roman30Wo 0" ` .  @n?" dd@  @@`` (D !  `r$Nsܦ?I8Zir$ 60ߵ!| :ii2$I߼0\"$#+S#m+L"$H3i6fM"$F|>tNd[I$"$Dmc)|$r' 0AA @?O ʚ;>a8ʚ;g4kdkd0dppp@ <4!d!d 0L4<4dddd 0L4 <4BdBd. 0L80___PPT10 ? %vTheraLife Eye  Oral Treatment for Dry Eye and Eye Fatigue(<+Double Blind Placebo Controlled Conducted by an independent CRO - Human Research and Study Center Clinical Sites = 6 Total patients = 83 Participating OD s  partial list Todd Severin, MD Ron Seger OD, FAAO Burton Worrell, OD Don Robinson, OD Somi Oh, OD David Moline, OD.ZeZe,.$TheraLife Eye Clinical Trial Summary%%(Effective in symptom relieve during first week Measured parameters: Red - Tear Breakup Test Burning - Zone Quick Dry Blurring Blink Tired Contact lens discomfort Overall discomfort 6DwDxGEnd Point Analysis (Repeat Measures Variance Analysis: Group x Time):H6X4 $B! $F" $ ` ` ̙33` 333MMM` ff3333f` f` f` 3>?" dd@,|?" dd@   " @ ` n?" dd@   @@``PR    @ ` ` p>> $(    6(n P  T Click to edit Master title style! !  0p   RClick to edit Master text styles Second level Third level Fourth level Fifth level!     S  0u ``  X*  0({ `   Z*  0 `   Z*H  0޽h ? ̙33 Default Design @p(  p p 0Љ P"   X*  p 0`Չ  "  Z*  p 6ى P   X*  p 6މ    Z* H p 0޽hx ? ̙3380___PPT10.|0  ,0$00/(  ,F /   /    BCDEDF.+@    `V%T ./  # D/ B  3 .B  3  .!B  3 .!7B  3 .7TB   3 .TiB   3 .iB   3 .B   3 !.B   3 #.B  3 &.B  3 '.B  3 +.B  3 ..-B  3 /.-BB  3 1.B_B  3 4._uB  3 8.uB  3 :.B  3 ;.B  3 >.B  3 A.B  3 D. B  3 G. "B  3 H."8B  3 K.8UB  3 O.UkB  3 Q.kB   3 T.B ! 3 U.B " 3 X.B # 3 \.B $ 3 ].B % 3 `.B & 3 c..B ' 3 g..KB ( 3 j.K`B ) 3 k.`vB * 3 n.vB + 3 p.B , 3 t.B - 3 w.B . 3 y.B / 3 {.B 0 3 .#B 1 3 .#@B 2 3 .@VB 3 3 .VlB 4 3 .lB 5 3 .B 6 3 .B 7 3 .B 8 3 .B 9 3 .B : 3 .B ; 3 ./B < 3 ./LB = 3 .LaB > 3 .a~B ? 3 .~B @ 3 .B A 3 .B B 3 .B C 3 .B D 3 .B E 3 .%B F 3 .%AB G 3 .AWB H 3 .WtB I 3 .tB J 3 .B K 3 .B L 3 .B M 3 .B N 3 .B O 3 .B P 3 .7B Q 3 .7MB R 3 .McB S 3 .cB T 3 .B U 3 .B V 3 .B W 3 .B X 3 .B Y 3 . B Z 3 . - B [ 3 .- C B \ 3 .C X B ] 3 .X u B ^ 3 .u  B _ 3 .  B ` 3 .  B a 3 .  B b 3 .  B c 3 .  B d 3 .  B e 3 . 8 B f 3 .8 N B g 3 .N k B h 3 .k  B i 3 .  B j 3 .  B k 3 .  B l 3 .  B m 3 .  B n 3 .  B o 3 . . B p 3 .. D B q 3 .D a B r 3 .a v B s 3 .v  B t 3 .  B u 3 .  B v 3 .  B w 3 .  B x 3 .  B y 3 . $ B z 3 .$ : B { 3 .: O B | 3 .O l B } 3 .l  B ~ 3 .  B  3 .  B  3 .  B  3 .  B  3 .  B  3 .  <  # . /   BCDE$F. XX@`-  B;C DEDF.A ;;;;; ; ; ; @    `y\-   BYC\DEDF.`b`bi+\\\\YYYYY\Y\Y\Y\\@    `7\   BYC[DEDF.i+[[[[YYYYY[Y[Y[Y[[@    `7\  BCDEF&A}m}m@`7\   BRCUDEDF.i+UUUURRRRRURURURUU@    `TF`  0A?v  0, j Copyright, 2000 TheraLife Inc..! 2 x  c $/P@`    x  c $0     B2r0 @ TheraLife  H  0޽h ? ̙330  Q0I0P/(  ,F /   /    BCDEDF.+@    `V%T ./  # D/ B  3 .B  3  .!B  3 .!7B  3 .7TB   3 .TiB   3 .iB   3 .B   3 !.B   3 #.B  3 &.B  3 '.B  3 +.B  3 ..-B  3 /.-BB  3 1.B_B  3 4._uB  3 8.uB  3 :.B  3 ;.B  3 >.B  3 A.B  3 D. B  3 G. "B  3 H."8B  3 K.8UB  3 O.UkB  3 Q.kB   3 T.B ! 3 U.B " 3 X.B # 3 \.B $ 3 ].B % 3 `.B & 3 c..B ' 3 g..KB ( 3 j.K`B ) 3 k.`vB * 3 n.vB + 3 p.B , 3 t.B - 3 w.B . 3 y.B / 3 {.B 0 3 .#B 1 3 .#@B 2 3 .@VB 3 3 .VlB 4 3 .lB 5 3 .B 6 3 .B 7 3 .B 8 3 .B 9 3 .B : 3 .B ; 3 ./B < 3 ./LB = 3 .LaB > 3 .a~B ? 3 .~B @ 3 .B A 3 .B B 3 .B C 3 .B D 3 .B E 3 .%B F 3 .%AB G 3 .AWB H 3 .WtB I 3 .tB J 3 .B K 3 .B L 3 .B M 3 .B N 3 .B O 3 .B P 3 .7B Q 3 .7MB R 3 .McB S 3 .cB T 3 .B U 3 .B V 3 .B W 3 .B X 3 .B Y 3 . B Z 3 . - B [ 3 .- C B \ 3 .C X B ] 3 .X u B ^ 3 .u  B _ 3 .  B ` 3 .  B a 3 .  B b 3 .  B c 3 .  B d 3 .  B e 3 . 8 B f 3 .8 N B g 3 .N k B h 3 .k  B i 3 .  B j 3 .  B k 3 .  B l 3 .  B m 3 .  B n 3 .  B o 3 . . B p 3 .. D B q 3 .D a B r 3 .a v B s 3 .v  B t 3 .  B u 3 .  B v 3 .  B w 3 .  B x 3 .  B y 3 . $ B z 3 .$ : B { 3 .: O B | 3 .O l B } 3 .l  B ~ 3 .  B  3 .  B  3 .  B  3 .  B  3 .  B  3 .  <  # . /   BCDE$F. XX@`-  B;C DEDF.A ;;;;; ; ; ; @    `y\-   BYC\DEDF.`b`bi+\\\\YYYYY\Y\Y\Y\\@    `7\   BYC[DEDF.i+[[[[YYYYY[Y[Y[Y[[@    `7\  BCDEF&A}m}m@`7\   BRCUDEDF.i+UUUURRRRRURURURUU@    `TF`  0A?v  0  j Copyright, 2000 TheraLife Inc..! 2 ~  s * @`P   r  S , `    B`4 e/TheraLife Eye Clinical Trial September, 2001 00H  0޽h ? ̙33g3  33`2(  ,F /   /    BCDEDF.+@    `V%T ./  # D/ B  3 .B  3  .!B  3 .!7B  3 .7TB   3 .TiB   3 .iB   3 .B   3 !.B   3 #.B  3 &.B  3 '.B  3 +.B  3 ..-B  3 /.-BB  3 1.B_B  3 4._uB  3 8.uB  3 :.B  3 ;.B  3 >.B  3 A.B  3 D. B  3 G. "B  3 H."8B  3 K.8UB  3 O.UkB  3 Q.kB   3 T.B ! 3 U.B " 3 X.B # 3 \.B $ 3 ].B % 3 `.B & 3 c..B ' 3 g..KB ( 3 j.K`B ) 3 k.`vB * 3 n.vB + 3 p.B , 3 t.B - 3 w.B . 3 y.B / 3 {.B 0 3 .#B 1 3 .#@B 2 3 .@VB 3 3 .VlB 4 3 .lB 5 3 .B 6 3 .B 7 3 .B 8 3 .B 9 3 .B : 3 .B ; 3 ./B < 3 ./LB = 3 .LaB > 3 .a~B ? 3 .~B @ 3 .B A 3 .B B 3 .B C 3 .B D 3 .B E 3 .%B F 3 .%AB G 3 .AWB H 3 .WtB I 3 .tB J 3 .B K 3 .B L 3 .B M 3 .B N 3 .B O 3 .B P 3 .7B Q 3 .7MB R 3 .McB S 3 .cB T 3 .B U 3 .B V 3 .B W 3 .B X 3 .B Y 3 . B Z 3 . - B [ 3 .- C B \ 3 .C X B ] 3 .X u B ^ 3 .u  B _ 3 .  B ` 3 .  B a 3 .  B b 3 .  B c 3 .  B d 3 .  B e 3 . 8 B f 3 .8 N B g 3 .N k B h 3 .k  B i 3 .  B j 3 .  B k 3 .  B l 3 .  B m 3 .  B n 3 .  B o 3 . . B p 3 .. D B q 3 .D a B r 3 .a v B s 3 .v  B t 3 .  B u 3 .  B v 3 .  B w 3 .  B x 3 .  B y 3 . $ B z 3 .$ : B { 3 .: O B | 3 .O l B } 3 .l  B ~ 3 .  B  3 .  B  3 .  B  3 .  B  3 .  B  3 .  <  # . /   BCDE$F. XX@`-  B;C DEDF.A ;;;;; ; ; ; @    `y\-   BYC\DEDF.`b`bi+\\\\YYYYY\Y\Y\Y\\@    `7\   BYC[DEDF.i+[[[[YYYYY[Y[Y[Y[[@    `7\  BCDEF&A}m}m@`7\   BRCUDEDF.i+UUUURRRRRURURURUU@    `TF`  0A?vx  c $ h2TheraLife Eye Clinical Trial September 18, 2001 33  B.K ` G T  3Dry  B`O@ ' |  5Tired  BRP D  < Contact Lens   BեS\  7Burning  BӤlZP@T  BOverall DiscomfortH  0޽h ? ̙33y2  )2!2p1(  ,F /   /    BCDEDF.+@    `V%T ./  # D/ B  3 .B  3  .!B  3 .!7B  3 .7TB   3 .TiB   3 .iB   3 .B   3 !.B   3 #.B  3 &.B  3 '.B  3 +.B  3 ..-B  3 /.-BB  3 1.B_B  3 4._uB  3 8.uB  3 :.B  3 ;.B  3 >.B  3 A.B  3 D. B  3 G. "B  3 H."8B  3 K.8UB  3 O.UkB  3 Q.kB   3 T.B ! 3 U.B " 3 X.B # 3 \.B $ 3 ].B % 3 `.B & 3 c..B ' 3 g..KB ( 3 j.K`B ) 3 k.`vB * 3 n.vB + 3 p.B , 3 t.B - 3 w.B . 3 y.B / 3 {.B 0 3 .#B 1 3 .#@B 2 3 .@VB 3 3 .VlB 4 3 .lB 5 3 .B 6 3 .B 7 3 .B 8 3 .B 9 3 .B : 3 .B ; 3 ./B < 3 ./LB = 3 .LaB > 3 .a~B ? 3 .~B @ 3 .B A 3 .B B 3 .B C 3 .B D 3 .B E 3 .%B F 3 .%AB G 3 .AWB H 3 .WtB I 3 .tB J 3 .B K 3 .B L 3 .B M 3 .B N 3 .B O 3 .B P 3 .7B Q 3 .7MB R 3 .McB S 3 .cB T 3 .B U 3 .B V 3 .B W 3 .B X 3 .B Y 3 . B Z 3 . - B [ 3 .- C B \ 3 .C X B ] 3 .X u B ^ 3 .u  B _ 3 .  B ` 3 .  B a 3 .  B b 3 .  B c 3 .  B d 3 .  B e 3 . 8 B f 3 .8 N B g 3 .N k B h 3 .k  B i 3 .  B j 3 .  B k 3 .  B l 3 .  B m 3 .  B n 3 .  B o 3 . . B p 3 .. D B q 3 .D a B r 3 .a v B s 3 .v  B t 3 .  B u 3 .  B v 3 .  B w 3 .  B x 3 .  B y 3 . $ B z 3 .$ : B { 3 .: O B | 3 .O l B } 3 .l  B ~ 3 .  B  3 .  B  3 .  B  3 .  B  3 .  B  3 .  <  # . /   BCDE$F. XX@`-  B;C DEDF.A ;;;;; ; ; ; @    `y\-   BYC\DEDF.`b`bi+\\\\YYYYY\Y\Y\Y\\@    `7\   BYC[DEDF.i+[[[[YYYYY[Y[Y[Y[[@    `7\  BCDEF&A}m}m@`7\   BRCUDEDF.i+UUUURRRRRURURURUU@    `TF`  0A?v  0t j Copyright, 2000 TheraLife Inc..! 2 ~  s *P    0 BA w? w   B@r0F @   <$E )Tear Breakup Test (Change from Baseline) L*0$$  <D hP d" 0.016: &H  0޽h ? ̙33}2  -2%21(  ,F /   /    BCDEDF.+@    `V%T ./  # D/ B  3 .B  3  .!B  3 .!7B  3 .7TB   3 .TiB   3 .iB   3 .B   3 !.B   3 #.B  3 &.B  3 '.B  3 +.B  3 ..-B  3 /.-BB  3 1.B_B  3 4._uB  3 8.uB  3 :.B  3 ;.B  3 >.B  3 A.B  3 D. B  3 G. "B  3 H."8B  3 K.8UB  3 O.UkB  3 Q.kB   3 T.B ! 3 U.B " 3 X.B # 3 \.B $ 3 ].B % 3 `.B & 3 c..B ' 3 g..KB ( 3 j.K`B ) 3 k.`vB * 3 n.vB + 3 p.B , 3 t.B - 3 w.B . 3 y.B / 3 {.B 0 3 .#B 1 3 .#@B 2 3 .@VB 3 3 .VlB 4 3 .lB 5 3 .B 6 3 .B 7 3 .B 8 3 .B 9 3 .B : 3 .B ; 3 ./B < 3 ./LB = 3 .LaB > 3 .a~B ? 3 .~B @ 3 .B A 3 .B B 3 .B C 3 .B D 3 .B E 3 .%B F 3 .%AB G 3 .AWB H 3 .WtB I 3 .tB J 3 .B K 3 .B L 3 .B M 3 .B N 3 .B O 3 .B P 3 .7B Q 3 .7MB R 3 .McB S 3 .cB T 3 .B U 3 .B V 3 .B W 3 .B X 3 .B Y 3 . B Z 3 . - B [ 3 .- C B \ 3 .C X B ] 3 .X u B ^ 3 .u  B _ 3 .  B ` 3 .  B a 3 .  B b 3 .  B c 3 .  B d 3 .  B e 3 . 8 B f 3 .8 N B g 3 .N k B h 3 .k  B i 3 .  B j 3 .  B k 3 .  B l 3 .  B m 3 .  B n 3 .  B o 3 . . B p 3 .. D B q 3 .D a B r 3 .a v B s 3 .v  B t 3 .  B u 3 .  B v 3 .  B w 3 .  B x 3 .  B y 3 . $ B z 3 .$ : B { 3 .: O B | 3 .O l B } 3 .l  B ~ 3 .  B  3 .  B  3 .  B  3 .  B  3 .  B  3 .  <  # . /   BCDE$F. XX@`-  B;C DEDF.A ;;;;; ; ; ; @    `y\-   BYC\DEDF.`b`bi+\\\\YYYYY\Y\Y\Y\\@    `7\   BYC[DEDF.i+[[[[YYYYY[Y[Y[Y[[@    `7\  BCDEF&A}m}m@`7\   BRCUDEDF.i+UUUURRRRRURURURUU@    `TF`  0A?v  0 j Copyright, 2000 TheraLife Inc..! 2 ~  s *@P    0 HA u?p u   Brs f0TheraLife Eye Clinical Trial September, 2001 11  <QC i!Zone Quick (Change from Baseline)," 6  <p/W hP d" 0.051: &H  0޽h ? ̙332  72/2 1(  ,F /   /    BCDEDF.+@    `V%T ./  # D/ B  3 .B  3  .!B  3 .!7B  3 .7TB   3 .TiB   3 .iB   3 .B   3 !.B   3 #.B  3 &.B  3 '.B  3 +.B  3 ..-B  3 /.-BB  3 1.B_B  3 4._uB  3 8.uB  3 :.B  3 ;.B  3 >.B  3 A.B  3 D. B  3 G. "B  3 H."8B  3 K.8UB  3 O.UkB  3 Q.kB   3 T.B ! 3 U.B " 3 X.B # 3 \.B $ 3 ].B % 3 `.B & 3 c..B ' 3 g..KB ( 3 j.K`B ) 3 k.`vB * 3 n.vB + 3 p.B , 3 t.B - 3 w.B . 3 y.B / 3 {.B 0 3 .#B 1 3 .#@B 2 3 .@VB 3 3 .VlB 4 3 .lB 5 3 .B 6 3 .B 7 3 .B 8 3 .B 9 3 .B : 3 .B ; 3 ./B < 3 ./LB = 3 .LaB > 3 .a~B ? 3 .~B @ 3 .B A 3 .B B 3 .B C 3 .B D 3 .B E 3 .%B F 3 .%AB G 3 .AWB H 3 .WtB I 3 .tB J 3 .B K 3 .B L 3 .B M 3 .B N 3 .B O 3 .B P 3 .7B Q 3 .7MB R 3 .McB S 3 .cB T 3 .B U 3 .B V 3 .B W 3 .B X 3 .B Y 3 . B Z 3 . - B [ 3 .- C B \ 3 .C X B ] 3 .X u B ^ 3 .u  B _ 3 .  B ` 3 .  B a 3 .  B b 3 .  B c 3 .  B d 3 .  B e 3 . 8 B f 3 .8 N B g 3 .N k B h 3 .k  B i 3 .  B j 3 .  B k 3 .  B l 3 .  B m 3 .  B n 3 .  B o 3 . . B p 3 .. D B q 3 .D a B r 3 .a v B s 3 .v  B t 3 .  B u 3 .  B v 3 .  B w 3 .  B x 3 .  B y 3 . $ B z 3 .$ : B { 3 .: O B | 3 .O l B } 3 .l  B ~ 3 .  B  3 .  B  3 .  B  3 .  B  3 .  B  3 .  <  # . /   BCDE$F. XX@`-  B;C DEDF.A ;;;;; ; ; ; @    `y\-   BYC\DEDF.`b`bi+\\\\YYYYY\Y\Y\Y\\@    `7\   BYC[DEDF.i+[[[[YYYYY[Y[Y[Y[[@    `7\  BCDEF&A}m}m@`7\   BRCUDEDF.i+UUUURRRRRURURURUU@    `TF`  0A?v  0 j Copyright, 2000 TheraLife Inc..! 2 ~  s *|P    0 HA y? y   Bhr c k5TheraLife Eye Clinical Trial September, 2001 66  <( n&Dry Eye Symptom (Change from Baseline),'6$  <5 hP d" 0.001: &H  0޽h ? ̙331 *xY}lT}w 0&q6`4ĭk>/2kmDTPS) iQD-iQJQjG+\*QۨR?jRX%UP_3ow߻`GBe~;W//|(D\`Jd2irOrG@9gG44T˽U>:gH1FǃP#~<7z? v&;0%3XQLu\10.: ;W9򜦪=Cgig[?GMt96䁦ryMуZZ*-rP T=z TzǛ(ʻ(B(Ͼ@Owow{_tkOhGVkCv fSGfz3S՟Rv/}+a=|ڈ)] ¥ixcyeym՟i2R{i M_JTjjSͽVȔJ> #jc|eh*ʅ Ckp(yhp\꠴8:7Jy Z leCEz`\ ϐ/+x><@0 'ʕ+ƥÒ"_A3d{xɲۓLvos:Pl@ @BblWZݹryI9.X#[:8XnX5ʼ.y!jg=f{o8*,7 9nI;N'>:yP~7*֮&N$zCǭn={ê$Rh=d64]zP8:[^LyT栾©~@XkFbev1_y/sr ;qtGZE;[ut=u6bk[(o%QƑ7 N`euLf X[BSũa:PxVC{68HVof8ao~{ѾOX匓p8tT :~-UBR ]HD~wb l{H/<"+uvY2G RmX-VYwx-Kd:+s6̚}r'9%qn1WXƃ.\&TYN!-/;.Ģ c̎daoJ&xzrH;\Ӊ—p*:Yf,~)aS/%|6x4d(?^/mx*6ni/kxSr]| ˄w|cja,%ȓs K%:_<~{$:8 &5wv%zǣM]#z&TOڣBB#wZBQ-m{BP%m[:ۨߖ)iגyFF.q M*ZhDm+cj|~@Q=)xR/ <'9Lk xۅuB#wWZ?s~;|s3#J~ q>6KX,aF5Zb%!,6dh;i04bZY]u-SjYb,vbs 95qmzLO_e'9W}FNjMhlb>Vg:7jr+-/4"HEj$fkd O]y}=f/wONtnNGlPϳAk8L_flVqV ez~YuIX>@tv1B| MޑcpEjމGG`c'$F&"Sʼ+TDOhkTEi,X< (-r;dzggg#?SJ"Τf^~UDj*;SwCqΗ0'dv%=[]/zK2PvWf{ 6xZ LT>7ïT O(KP[,QHQ`טlRtkX#M]knLlK6ImeӦY5["nmmLϹKMw|{λo_\`x$ ċ `H$ؑ*Eʐ>C" "!vyXBK#-@AEZi1Rҧdߧ4C/~ ^;LXQcQ>0S ο.;e*xO r Ct:K:idҿc?|/@ɦ'ފuZf[4GZiRR!R)TTTiRR9JUHH*A !U!U# AZ,sH#m@OWa1>pVtܱOk@_oo@`G_CP(׎-]kjlm[u T:6Yi6S6oµmAXAnX4`I8^LݴXEޗƴ>7V(E*C=I \IpUm'ʀ,oʤbMص:vrL`ǡ9TEx#ʡTY&ȗuc1uA?1gk6ۃm=4ܲ{>ݦ#~E`"VkӢWq|OJ '+tKN!F8zp^6 \x<9+'%<U_ BMD`hhHt ^/ǖrxE6 ľx;#P32|&D;;fANȫ!\5fg񧑰Jm3lp嶁1Z""iSؾǦ>kلY며?|H,u?݁*2j9Xk,L'{Uum'&J bqP_'X\X{}$Y\s3q``q\:ZAG)W.>q vmT۾ E'⪹"Yhu6Ȍ̲yK~J,`|OM3LJ-͆m;DV=#Ͽx2qp{Z;M;qHڙ8γ>b0ho{83)OuD@uSXW(Αؙ2L.ZdNh .f窀i6.A5e׸!}kȍ$ș]k=&X6ۍvڙ{$h >y!1/<$e#Kh8BRYDJerH)O@ypfbf5}捝cOiygLfM3?ح83YMU90]T;}y.fxls;m'%;cmlәMp݌,w ۗB=-/o*vxlHCi(Wzu,,">ε|°hL)2^qLr\*4F_oA;]sa!ʇ,q~,[{vUJHdgv CƨOd!߿滦~/{ɖ<>a2}O Wy\3]d C*v? ԆOs (єDKחZ^iIl,hnBk5RC.kX+98[L!D j((ް k);y G3뙴sՄ2j#7B|5תyԼV?ּa;y4A AU~nw\;y4)/y;k(OyΖo. k|P?kK_'C'P'CJXͿBoðZ2S5PÁ@y}S.5<E"y?bnǴǠ^$l㲖w˘cڎ1mǘCڎ!mǐ=888vĬ ׌赉) T-XZU12Bj9)z=znFQThd,yq܎sEPC=s;vTvtk;=hvh;Z<(ճ^ռx; ' Y1vء9mLJvPYKtA6ĦM]i46KXHiɣL0I|9BEy'K%^,("K|~˯/x*ĉ#H:mW&˒BwʱbiQ}D9*RbY!eDY&$ "ʻaf|sG|(DƟ1>>gl?dƏ}UJHĿbj1Zrm*?Roi`۳)1g}mOH+HK h*S\Ox/hD'yuF̞co(bJAv:; F =~u6LT<;bHc?@|ebdx8@|ԢӽWiO>!Kɛړ7sG/+v`+#Q=/ /?d;/o -ϔ$SztfD^?'3~7 ۗNomxq&i2WI 6xZklT>s} Y?B\72˫UHu!MZ*pU!H n-5J"$Z9JJS)}4ݻwV~sfwqfws_$pgLh;~tT yJDL|9JDJ*I(QTLuϴ!J؇^8wMqƘ(KU*nTw^+a@2~$dӛJ^ Wr/@;{?S $ O;u~ Z=haψ]תr-Q2? e: (5(P((u(( (F2e'P,@iBy %Ҍ҂GYq'PDYxP^K} z>]y`W%ɵzEruleMwujz>Z/j,[j[P'K۷a&\T[/F.2)n$5ɶt l5*j6?d?,$b ^Ki n҇e>S({'n#1 .X Z1~)bX4Nkp;C%0oWӟճܐK,a]/!H;rDʜ?x|a``@a6,mD>Qghdc~|RBIQ~8y$nwG闂Xxa[.w#%r!D8rO,Kޗt%G= [=fEA+(:N56&;6ǞS';MߡƭӂhYV! yAU,Z\)F8,Bi'[ZDP'hS* Q-[[hLBn_J5PTSnR^&.~,CZi/B߿>``-ZEHV{iő[ؚȶxBCy5썕޿$Ȑ>MrE+פVE3TJ,*Q*je66*cWdlg0F1|15e*eҵ0|14lhܗea2,c[X-c݆e<Ud8ca54̑X0v; r&c5g|gMhbU'u޸ku\8.귓-X1E+ކA\uV3Jybݖc$YYHD"&l`ހ}Zct s05R?S؏)~d?n7~\g?q8~F?2P]=c*na\. #]l1}Mpv13Kp&oY&ca`bcoƮ;kH)#GH?RGHb?RG*b?R;Jʜ)a-sY'Sq@ ;DӰVh^Χ""iT'V ruAW}02un੪?| H䏍.۞ ¨OCɦ']ފ{`7ʦu=&$|ҵ$Ϯ?.)G"%f!F*&HsHH!2rH#-@@Zi1RSHajR-"-CZxf\Ϊm7vli ¹Wwut,>ԼUUlZ\~ᥑʴf6~.M:ga%liPy,♶C[EY>;-]/3Pb*?~&2!/g4ɺv Jض@ V@hqHچ]0(*_|'O:+ٺD\ 4F`KӳUW/I?zx]Ўy?}ôVA'slƷI/ |[D~oǷXz xu^}ٙbZT5t$wP8V6~jQ6v>1ճc:KD.QV$:$U~D`h(.\1*6˱eE3#~>ط4vG "CC#7Q?R'OĴ#H^hȶ-`b&`Yc\EʧRY[L1rXg,}Jax;z&n5ūKZj2\P .(bC>Tkbbj]b2M/C7? g:yБ*Eq1 [)gWfnY.}w!^E}rqK}5\a!+H+݃ݎ:0rh'~&ΙnȺjGE2 M3\0)QsdheThI\zࠚ5$dB>kQz2c2:b㬻9H3#ԝ%"Hwq? 7NgE\y,GAt-yn#JI m'} c[tzbG^Nht{ۗw3B=ZorYރv ,xmD0Zk2V*+YKjĎ<ȓ,_ @Bc  Y͇6\t dz|hjW%?ܮάapB!OJ&W]RXܫ56}86`u"-W|XDm1NS"Z)Ҳ1NiMOzWRK.?†s|fKt>WƝt1OaZKWw7!rp˾ҒyZ%.TOyh޾hcIttfdOlFos^Hc{ :šI(x~)D9^dn4*핔g!c<+>M71 '㭴ORjhqDkvD=f u- SsK5Ps{ kl>q@q@q GGGqFqFq&P&N'SqDX Gs#eSKVlf}\v1IҊ2A*.*v vNF7y Q}5e>oDϳjl,&krq6}dgl %aR#wr]p$wv?whQ> #2sVlWk]aNZT?97g'GWL|C`c&9Jڏ1^H N{}g=չA.3Nߩf›gi,gxɴ_4I:S_ / o`~ܮQ!3y˙b◴5eŨ/b)P~vEww7+9SWMj%땼{}Enj%=U߰ \Fz,k.ߗy~hy rEg=#+#?;ŻnW]J&͛;&5/D5>r\ ) 'O?+J< U>`B lFExHuOh+'0^ `h    (3Dry Eye Syndrome Advances and Treatment StrategiesiPreferred CustomervIgorrre31rMicrosoft PowerPointnce@V{@0 @d,GV]g  . & &&#TNPP 2OMi & TNPP &&TNPP    --- !---&G&qw@W yLSwUSw0- &Gy& & F3&'wF--$ (((x(xCxCxCC(--&& 3--- !k --- --- !k$ ------ !k) ------ !k, ------ !k1 ------ !k5 ------ !k8 ---!--- !k= ---#--- !kA ---&--- !kF ---'--- !kJ ---+--- !kM ---.--- !kR ---/--- !kV ---1--- !kY ---4--- !k^ ---8--- !kb ---:--- !kg ---;--- !kk --->--- !kn ---A--- !ks ---D--- !kw ---G--- !k| ---H--- !k ---K--- !k ---O--- !k ---Q--- !k ---T--- !k ---U--- !k ---X--- !k ---\--- !k ---]--- !k ---`--- !k ---c--- !k ---g--- !k ---j--- !k ---k--- !k ---n--- !k ---p--- !k ---t--- !k ---w--- !k ---y--- !k ---{--- !k ------ !k ------ !k ------ !k ------ !k ------ !k ------ !k ------ !k ------ !k ------ !k ------ !k ------ !k ------ !k ------ !k ------ !k ------ !k  ------ !k ------ !k ------ !k ------ !k ------ !k! ------ !k& ------ !k) ------ !k- ------ !k2 ------ !k6 ------ !k: ------ !k> ------ !kB ------ !kG ------ !kJ ------ !kO ------ !kS ------ !kW ------ !k[ ------ !k_ ------ !kc ------ !kh ------ !kk ------ !kp ------ !kt ------ !kw ------ !k| ------ !k ------ !k ------ !k ------ !k ------ !k ------ !k ------ !k ------ !k ------ !k ------ !k ------ !k ------ !k ------ !k ------ !k ------ !k ------ !k ------ !k ------ !k ------ !k ------ !k ------ !k ------ !k ------ !k ------ !k ------ !k ------ !k ------ !k ------ !k ------ !k ------ !k ------ !k ------ !k ------ !k ------ !k  ------ !k  ------ !k ------ !k ------ !k ------ !k ------ !k! ------ !k& ------ !k* ------ !k/ ---&&T--$ TTTXT--&&?&--yB(-$ ?????---&&&3H`b-`b-$ 444I4III4--&&3J--$ 444K4KKK4--&&4K&--yB(-$49NK4---&&&8M--$ 999N9NNN9--&&=H.  --W g     -- AV$)4 4   2 @? @) < 2       p U q, Y K K Yw q[ E 7 )      2 < @E @# 2   44 4 --B$r Lo je V B +       w k zc \c @i "u       ' > U e o ,r Gr L$           --$T= 1 !     / J h     1  * * : Z S R m Z  | M S )* 1 )  ` = ' | Z e C  a &  | S L i    + . M R a k a a M 3  ' N  C m  N ; ] w ~ w ~ e c C ; *   h 1 = 1 $a  w q q s Z 8 & i3 <S |   f K| S  t i $,    x; Ui ; `   { G    xL < ^ > Z ` ` R 69 Z t  ! ^    , N r, { U )J mJ N b  " N ^4 q <    m K ) T     ) T w   9 * h )  H s    = ; q e ;  l$4o  h > + 3 3 x C !   aw ,q q    h$ NL +o    ~o   T ; t; I c ~ +%    >% {A i    o ; U    t  Xo - -%  .     -$     0$  7 #                % /  -% a [%  -$   D 8 -%  $-$   P D -%  U -$   w -%  -$      -H$"r Lo fh ~\ J 7        { m e na Sa 8g q        ( > P ` l p 8r L-B$      8 S n         { m e la Ra 8g s        -.% 2 2   $$ 2B =b @ @ < 2 "   ( = W s s _ O@% 8 ?B Sn g q y }$ yN q| e S < 4 %       a 6   2 P z m ^ D 2 % ur6 %6 9 q%a6 W%6 )%R 6 % 6 Q%B 6  % 6 , %4 6 g f % ..% 4 4   $ 4 =j BJ B+ = 2 $     v Z u< a Q@%8?U_g3s{ } { sQ g' S ? 7 '       c 8  | | ` ^ < G  4 %u[6 %6 s%l6 : Y%6 +%{6 %6 S% 6 % 6 % 6 f f %L 0-T$(9 W {   k 29 U w    > e% 9 M ,  [ *   . M u b < A e   h I     m T 9 r$7   s g c e o : V j { =      A u  a 7  ,   wA dV Ih &o o f V I ( A J P Y Y R J 09 G V r I 4 y {     2$Y ' J t     0 [   m I *     h h2 LI 8Y '&$    + I3 q3 - / ' h I 5 !  j  |$<v A U m       !  { d "R CK ]E }E M Z J ? ? aJ +Z n     He 5A !      s% _= S] A= Y. q% $ ) = W }   6      q ^ Ov A0$ v Q m   1 Y  { a {    ]x 1^ E +  b  v2$  & 9 T q     )  H *     } g M 9 & H$" ' @ W! u!     Y 3   2  U u o F   3 U        k P 7 '($ vt ]   % N o o F   s G  vn$5C F c e s } w s a G  $ ( 9 f  ? g o E  v N 4    l a a h o N < ( F ] { u { i ! G U ] ] Y k C F 4$Z b     1 W  u %S ;' D D 7 p X < Z $ K /    P * s A } _ } o o Y A 7 / / K / $ / 9    * _ A R _ R o ` Y 7 / / / / $ $   -% 3 Y  M k y } o } g u S $%N - ? - *      # / G ] i M 5  %  b  r R 5 ) / %  r+ QA >Z 't    ~% x A%Y s  , D ]2 t %  & / 5 M W % R k R y f ? w % . %  i P/ 8M a %W E )' V p   %9 A M [ m  +%     6 X" { %    /%  - - #  {   %)  o U Q 6 5   -- --'&&--y-- @"Tahomaw@ aLSwUSw0- .72  Copyright, 2000 TheraLife Inc.       .--8`-- @Times New RomanLSwUSw0- .2 v,TheraLife Eye '!''. . 2 v.@Times New RomanLSwUSw0- .F2 *Oral Treatment for Dry Eye and Eye Fatigue     .--yQ-- @Times New RomanLSwUSw0- . 2  . .62 Double Blind Placebo Controlled.      . . 2  . .72  Conducted by an independent CRO     .